Evotec Valuation

Is EVT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EVT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EVT (€8.85) is trading below our estimate of fair value (€65.88)

Significantly Below Fair Value: EVT is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for EVT?

Key metric: As EVT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for EVT. This is calculated by dividing EVT's market cap by their current revenue.
What is EVT's PS Ratio?
PS Ratio2x
Sales€777.05m
Market Cap€1.57b

Price to Sales Ratio vs Peers

How does EVT's PS Ratio compare to its peers?

The above table shows the PS ratio for EVT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.9x
GXI Gerresheimer
1.3x9.7%€2.7b
1SXP SCHOTT Pharma KGaA
4.2x10.5%€4.0b
SRT3 Sartorius
4.5x9.3%€13.5b
BIO3 Biotest
1.5x3.6%€1.3b
EVT Evotec
2x12.1%€1.6b

Price-To-Sales vs Peers: EVT is good value based on its Price-To-Sales Ratio (2x) compared to the peer average (2.9x).


Price to Sales Ratio vs Industry

How does EVT's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
EVT 2.0xIndustry Avg. 4.4xNo. of Companies9PS03.67.210.814.418+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: EVT is good value based on its Price-To-Sales Ratio (2x) compared to the European Life Sciences industry average (4.3x).


Price to Sales Ratio vs Fair Ratio

What is EVT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EVT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2x
Fair PS Ratio2.6x

Price-To-Sales vs Fair Ratio: EVT is good value based on its Price-To-Sales Ratio (2x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EVT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.85
€11.04
+24.7%
45.7%€22.00€4.00n/a8
Dec ’25€8.83
€11.04
+25.0%
45.7%€22.00€4.00n/a8
Nov ’25€7.15
€10.65
+49.1%
48.7%€22.00€4.00n/a8
Oct ’25€6.21
€13.64
+119.8%
52.7%€30.00€4.00n/a10
Sep ’25€6.68
€13.64
+104.3%
52.7%€30.00€4.00n/a10
Aug ’25€8.48
€19.26
+127.2%
57.9%€50.00€10.00n/a11
Jul ’25€9.02
€20.79
+130.5%
55.4%€50.00€10.40n/a10
Jun ’25€8.66
€20.79
+140.2%
55.4%€50.00€10.40n/a10
May ’25€9.74
€24.20
+148.5%
45.4%€50.00€10.40n/a10
Apr ’25€14.47
€25.90
+79.0%
37.9%€50.00€14.00n/a10
Mar ’25€13.95
€23.67
+69.7%
26.2%€30.00€14.00n/a9
Feb ’25€13.56
€24.88
+83.5%
22.1%€30.00€15.40n/a8
Jan ’25€21.28
€29.68
+39.5%
28.8%€50.00€18.60n/a9
Dec ’24€18.41
€29.86
+62.2%
28.7%€50.00€18.60€8.839
Nov ’24€16.30
€31.01
+90.3%
24.6%€50.00€20.00€7.159
Oct ’24€18.90
€30.11
+59.3%
25.7%€50.00€20.00€6.2110
Sep ’24€21.74
€30.11
+38.5%
25.7%€50.00€20.00€6.6810
Aug ’24€23.91
€30.21
+26.3%
25.5%€50.00€20.00€8.4810
Jul ’24€20.61
€29.96
+45.4%
26.1%€50.00€20.00€9.0210
Jun ’24€20.88
€27.50
+31.7%
31.3%€50.00€20.00€8.6610
May ’24€16.63
€27.13
+63.2%
32.4%€50.00€20.00€9.7410
Apr ’24€19.44
€26.93
+38.6%
33.1%€50.00€20.00€14.4710
Mar ’24€16.61
€26.93
+62.1%
32.7%€50.00€20.00€13.9510
Feb ’24€17.88
€26.93
+50.7%
32.7%€50.00€20.00€13.5610
Jan ’24€15.26
€28.14
+84.4%
32.9%€50.00€21.00€21.289
Dec ’23€17.72
€28.39
+60.3%
32.0%€50.00€21.00€18.419

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies